SG11201901928SA - Mucoadhesive microorganism - Google Patents
Mucoadhesive microorganismInfo
- Publication number
- SG11201901928SA SG11201901928SA SG11201901928SA SG11201901928SA SG11201901928SA SG 11201901928S A SG11201901928S A SG 11201901928SA SG 11201901928S A SG11201901928S A SG 11201901928SA SG 11201901928S A SG11201901928S A SG 11201901928SA SG 11201901928S A SG11201901928S A SG 11201901928SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bacteria
- microorganism
- microorganisms
- pct
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title abstract 8
- 230000003232 mucoadhesive effect Effects 0.000 title abstract 2
- 241000894006 Bacteria Species 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 101100427060 Bacillus spizizenii (strain ATCC 23059 / NRRL B-14472 / W23) thyA1 gene Proteins 0.000 abstract 2
- 101100153154 Escherichia phage T5 thy gene Proteins 0.000 abstract 2
- 102000015728 Mucins Human genes 0.000 abstract 2
- 108010063954 Mucins Proteins 0.000 abstract 2
- 101100313751 Rickettsia conorii (strain ATCC VR-613 / Malish 7) thyX gene Proteins 0.000 abstract 2
- 102000007641 Trefoil Factors Human genes 0.000 abstract 2
- 108010007389 Trefoil Factors Proteins 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 101150072314 thyA gene Proteins 0.000 abstract 2
- -1 CmbA Proteins 0.000 abstract 1
- 101100349538 Dictyostelium discoideum numA gene Proteins 0.000 abstract 1
- 101000889485 Homo sapiens Trefoil factor 3 Proteins 0.000 abstract 1
- 241000194035 Lactococcus lactis Species 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 235000014897 Streptococcus lactis Nutrition 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 230000021164 cell adhesion Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 102000055380 human TFF3 Human genes 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940051875 mucins Drugs 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
Abstract
ORIBseRI Eco III BaeG I ApaLl Sfol Narl Kasl Fspl EcoRl Avail BtgZ I Scal Acul Acc651 Kpnl Agel Bsu361 2000 cmbA SSusp45 htff3 6000 1000 pAGX2005 (AGX No 3156) — 5000 6843 bps 4000 3000 / \ Em PthyA thyA 3' Hpal BspHI Afl III SgrDI (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 March 2018 (22.03.2018) WI P0 I PCT omit IIl °nolo III um Oil Oil °mono X10 mmIE (10) International Publication Number WO 2018/051223 A4 BamHI Eci I Mscl (51) International Patent Classification: C07K 14/705 (2006.01) (21) International Application Number: PCT/IB2017/055470 (22) International Filing Date: 11 September 2017 (11.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/394,024 13 September 2016 (13.09.2016) US (71) Applicant: INTREXON ACTOBIOTICS N.V. [BE/BE]; Technologiepark 4, B-9052 Zwijnaarde (BE). (72) Inventors: STEIDLER, Lothar; Bokslaarstraat 41, B-9160 Lokeren (BE). VANDENBROUCKE, Klaas; Bachtenboslaan 5, B-9840 De Pinte (BE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (54) Title: MUCOADHESIVE MICROORGANISM Xbal Sbfl Sapl Sphl Taul thyA 5' Clal BseYI Gsal Pmll SnaBI FIG. 1 (57) : The present disclosure provides genetically modified microorganisms bacteria or yeast) with enhanced mucin- (e.g., binding and/or cell-adhesion properties. For example, the present disclosure provides bacteria exhibiting increased in vitro binding to Caco-2 cells, and increased in vitro binding to mucins. Such microorganisms (e.g., bacteria) can be used, e.g., to deliver bioactive polypeptides to the gastrointestinal tract of a mammalian subject. Modifying the microorganism in the described manner allows for the modulation of gastrointestinal retention and transit times for the microorganism (e.g., bacterium). Exemplary microorganisms (e.g., lactic acid bacteria, such as Lactococcus lactis) contain an exogenous nucleic acid encoding a fusion protein containing a cell-adherence polypeptide, such as CmbA, and a mucin-binding polypeptide, such as a trefoil factor (TFF), e.g., human TFF3. The current disclosure further provides method for making and using the described microorganisms bacteria). (e.g., [Continued on next page] BsrG I Drdl Blpl WO 2018/051223 A4 MIDEDIMOMOIDEIREEMOOMMEMOHHOMOOMEEN UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with amended claims (Art. 19(1)) with sequence listing part of description (Rule 5.2(a)) Date of publication of the amended claims: 03 May 2018 (03.05.2018)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662394024P | 2016-09-13 | 2016-09-13 | |
PCT/IB2017/055470 WO2018051223A1 (en) | 2016-09-13 | 2017-09-11 | Mucoadhesive microorganism |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901928SA true SG11201901928SA (en) | 2019-04-29 |
Family
ID=60190901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901928SA SG11201901928SA (en) | 2016-09-13 | 2017-09-11 | Mucoadhesive microorganism |
Country Status (11)
Country | Link |
---|---|
US (3) | US10808014B2 (en) |
EP (1) | EP3512872A1 (en) |
JP (2) | JP7022743B2 (en) |
KR (2) | KR102469701B1 (en) |
CN (1) | CN109983028B (en) |
AU (2) | AU2017328129B2 (en) |
CA (1) | CA3035488A1 (en) |
IL (1) | IL265177A (en) |
RU (2) | RU2021135949A (en) |
SG (1) | SG11201901928SA (en) |
WO (1) | WO2018051223A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111491657A (en) | 2017-10-20 | 2020-08-04 | 哈佛学院院长及董事 | Artificial secretory peptides for heterologous protein production |
CN110129220B (en) * | 2019-04-30 | 2021-06-22 | 石河子大学 | Lactobacillus bulgaricus BSTS6-4 and application thereof |
CA3152665A1 (en) * | 2019-08-27 | 2021-03-04 | Tonix Pharma Limited | Modified tff2 polypeptides |
CA3156035A1 (en) * | 2019-09-27 | 2021-04-01 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Treatment of celiac disease |
WO2021158376A1 (en) * | 2020-02-06 | 2021-08-12 | Codexis, Inc. | Mucin-binding fusion proteins |
CN111690666B (en) * | 2020-07-30 | 2023-05-05 | 江苏食品药品职业技术学院 | Recombinant thaumatin II structural gene, expression vector, method for producing sweet protein and application |
KR102231437B1 (en) * | 2020-09-21 | 2021-03-24 | 주식회사 보삼바이오산업 | Manufacturing method of composition for the prevention or treatment of highly pathogenic avian influenza virus and composition for the prevention or treatment of highly pathogenic avian influenza virus using the same |
CN112195210B (en) * | 2020-10-24 | 2022-01-04 | 上海加新生物科技有限公司 | Production method of hyaluronic acid |
CN112708577B (en) * | 2020-12-31 | 2022-04-05 | 扬州大学 | Lactobacillus fermentum DALI02 with high intestinal adhesion and immunoregulation function and application thereof |
WO2022174226A1 (en) * | 2021-02-09 | 2022-08-18 | University Of Massachusetts | Intracellular delivery of therapeutic proteins designed to invade and autonomously lyse and methods of use thereof |
CN113684201A (en) * | 2021-08-27 | 2021-11-23 | 日照市畜牧兽医管理服务中心 | Breeding method for screening intestinal tract colonization probiotics based on Caco-2 cell high-efficiency mutagenesis |
CN114377117B (en) * | 2021-12-06 | 2023-11-10 | 中国医学科学院医学生物学研究所 | Oral type 1diabetes vaccine and preparation method thereof |
CN115197885B (en) * | 2022-09-13 | 2022-12-09 | 中国农业科学院北京畜牧兽医研究所 | Lactococcus garvieae LGM15, microbial inoculum and application |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB227835A (en) | 1924-01-15 | 1925-04-09 | Harry Odell | Improvements in feeding mechanism for embossing and other printing presses |
US4919918A (en) | 1988-03-14 | 1990-04-24 | Spectrum Consumer Products Co., Inc. | Non-alcoholic mouthwash |
US5972685A (en) | 1988-07-21 | 1999-10-26 | Iowa State University Research Foundation, Inc. | Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration |
GB9126306D0 (en) | 1991-12-11 | 1992-02-12 | Unilever Plc | Mouthwash compositions |
CA2130453A1 (en) | 1992-02-27 | 1993-09-02 | Richard W. F. Le Page | Heterologous gene expression in lactococcus, and the expression products threrefrom |
US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
US5700782A (en) | 1993-05-28 | 1997-12-23 | Abbott Laboratories | Enteral nutritional product |
AU2149495A (en) | 1995-04-11 | 1996-10-30 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Method for the construction of vectors for lactic acid bacte ria like lactobacillus such that the bacteria can efficientl y express, secrete and display proteins at the surface |
US5695746A (en) | 1995-07-28 | 1997-12-09 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Liquid dentifrice with mouthwash fresh taste |
AU1533697A (en) | 1996-01-24 | 1997-08-20 | Warner-Lambert Company | Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems |
GB9611364D0 (en) | 1996-05-31 | 1996-08-07 | Smithkline Beecham Plc | Composition |
WO1998011866A1 (en) | 1996-09-18 | 1998-03-26 | Erling Johansen | Mouthwash comprising calcium and phosphate ions in supersaturated solution |
US5869118A (en) | 1996-11-13 | 1999-02-09 | Abbott Laboratories | Gellan gum to improve physical stability of liquid nutritional products |
US6171611B1 (en) | 1997-11-12 | 2001-01-09 | Dante J. Picciano | Iodine-containing nasal moisturizing saline and mouthwash solutions |
US5897872A (en) | 1997-11-12 | 1999-04-27 | Picciano; Dante J. | Iodine-containing nasal moisturizing saline solution |
US6100388A (en) * | 1998-03-16 | 2000-08-08 | Biogaia Biologies Ab | Lactobacilli harboring aggregation gene as a vaccine delivery vehicle |
CN100358509C (en) | 1998-09-28 | 2008-01-02 | 沃纳-兰伯特公司 | Enteric and colonic delivery using HPMC capsules |
WO2000022909A2 (en) | 1998-10-19 | 2000-04-27 | Biotech Australia Pty. Limited | Systems for oral delivery |
DK1194554T3 (en) | 1999-07-05 | 2007-01-29 | Vlaams Interuniv Inst Biotech | Administration of tricyclic peptides |
WO2002090551A2 (en) | 2001-05-03 | 2002-11-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Self-containing lactococcus strain |
WO2002102403A1 (en) * | 2001-06-14 | 2002-12-27 | Novo Nordisk A/S | Mucosal repair by tff dimer peptides |
US20030219402A1 (en) | 2002-02-14 | 2003-11-27 | Rutter William J. | Chimeric molecules for cleavage in a treated host |
US20040131567A1 (en) | 2002-07-08 | 2004-07-08 | Wilkins Joe S. | Antibacterial topical formulations |
JP2007530034A (en) | 2004-03-23 | 2007-11-01 | エヌ.ブイ.・ヌートリシア | Novel mannose-specific adhesins and their use |
WO2006018446A2 (en) | 2004-08-20 | 2006-02-23 | Actogenix Nv | Method to improve lactococcus preservation |
CA2925307C (en) | 2005-08-30 | 2019-12-03 | Intrexon Actobiotics Nv | Novel treatment of chronic enterocolitis |
CA2631598C (en) | 2005-11-29 | 2017-06-27 | Actogenix Nv | Induction of mucosal tolerance to antigens |
US20090311249A1 (en) | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
ES2595729T3 (en) * | 2007-01-12 | 2017-01-03 | Intrexon Actobiotics Nv | Lactococcus promoters and their uses |
EP3351268B1 (en) | 2007-01-25 | 2020-08-05 | Intrexon Actobiotics NV | Treatment of immune disease by mucosal delivery of antigens |
US20100178273A1 (en) * | 2007-06-20 | 2010-07-15 | Actogenix Nv Corporation | Methods and compositions for treating mucositis |
AU2010209584C1 (en) * | 2009-02-02 | 2016-09-08 | Chr. Hansen A/S | Lactobacillus rhamnosus pilus polypeptides and methods for producing them |
CN102414310B (en) | 2009-04-30 | 2015-05-06 | 阿克图杰尼斯公司 | Cryoprotectants for freeze drying of lactic acid bacteria |
WO2012164083A1 (en) | 2011-06-01 | 2012-12-06 | Actogenix N.V. | Polycistronic expression system for bacteria |
DK2717712T3 (en) * | 2011-06-09 | 2019-12-16 | Novozymes As | Fusion of bioactive molecules |
EP2758512B1 (en) | 2011-09-23 | 2018-05-09 | Intrexon Actobiotics NV | Modified gram positive bacteria and uses thereof |
WO2013041673A1 (en) | 2011-09-23 | 2013-03-28 | Actogenix Nv | Modified gram positive bacteria and uses thereof |
EP2914274A4 (en) * | 2012-11-01 | 2016-07-20 | Sydney Children S Hospital Network Randwick And Westmead | Genetically-modified probiotic for treatment of phenylketonuria |
WO2016124239A1 (en) * | 2015-02-04 | 2016-08-11 | Aurealis Oy | Recombinant probiotic bacteria for use in the treatment of a skin dysfunction |
US10905727B2 (en) | 2016-01-14 | 2021-02-02 | Intrexon Actobiotics N.V. | Compositions and methods for the treatment of type 1 diabetes |
WO2018042390A1 (en) | 2016-09-02 | 2018-03-08 | Intrexon Actobiotics N.V. | Genetically modified bacteria stably expressing il-10 and insulin |
-
2017
- 2017-09-11 US US16/331,660 patent/US10808014B2/en active Active
- 2017-09-11 WO PCT/IB2017/055470 patent/WO2018051223A1/en unknown
- 2017-09-11 KR KR1020227000226A patent/KR102469701B1/en active IP Right Grant
- 2017-09-11 EP EP17791452.0A patent/EP3512872A1/en active Pending
- 2017-09-11 AU AU2017328129A patent/AU2017328129B2/en active Active
- 2017-09-11 JP JP2019513897A patent/JP7022743B2/en active Active
- 2017-09-11 CN CN201780069890.3A patent/CN109983028B/en active Active
- 2017-09-11 CA CA3035488A patent/CA3035488A1/en active Pending
- 2017-09-11 KR KR1020197009765A patent/KR102348734B1/en active IP Right Grant
- 2017-09-11 RU RU2021135949A patent/RU2021135949A/en unknown
- 2017-09-11 RU RU2019108553A patent/RU2762940C2/en active
- 2017-09-11 SG SG11201901928SA patent/SG11201901928SA/en unknown
-
2019
- 2019-03-05 IL IL265177A patent/IL265177A/en unknown
-
2020
- 2020-09-21 US US17/026,379 patent/US11384123B2/en active Active
-
2021
- 2021-04-27 AU AU2021202595A patent/AU2021202595B2/en active Active
-
2022
- 2022-02-07 JP JP2022016914A patent/JP7439148B2/en active Active
- 2022-06-06 US US17/832,745 patent/US20230013523A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2021202595A1 (en) | 2021-05-27 |
RU2762940C2 (en) | 2021-12-24 |
CN109983028A (en) | 2019-07-05 |
US11384123B2 (en) | 2022-07-12 |
JP2022084579A (en) | 2022-06-07 |
US20210070815A1 (en) | 2021-03-11 |
KR20220005641A (en) | 2022-01-13 |
US10808014B2 (en) | 2020-10-20 |
CA3035488A1 (en) | 2018-03-22 |
JP7439148B2 (en) | 2024-02-27 |
EP3512872A1 (en) | 2019-07-24 |
IL265177A (en) | 2019-05-30 |
CN109983028B (en) | 2023-10-20 |
KR102469701B1 (en) | 2022-11-22 |
RU2021135949A (en) | 2022-04-14 |
KR20190056387A (en) | 2019-05-24 |
RU2019108553A3 (en) | 2020-12-15 |
US20190194267A1 (en) | 2019-06-27 |
JP7022743B2 (en) | 2022-02-18 |
KR102348734B1 (en) | 2022-01-07 |
AU2017328129B2 (en) | 2021-01-28 |
RU2019108553A (en) | 2020-10-15 |
AU2021202595B2 (en) | 2022-02-17 |
US20230013523A1 (en) | 2023-01-19 |
JP2019530446A (en) | 2019-10-24 |
WO2018051223A4 (en) | 2018-05-03 |
WO2018051223A1 (en) | 2018-03-22 |
AU2017328129A1 (en) | 2019-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901928SA (en) | Mucoadhesive microorganism | |
SG11201906341XA (en) | Improved serum albumin binders | |
SG11201906264YA (en) | Improved serum albumin binders | |
SG11201806398YA (en) | Optimized factor viii genes | |
SG11201803169WA (en) | Cellulase variants and polynucleotides encoding same | |
SG11201806988UA (en) | Improved differentiation method | |
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201806758VA (en) | Vcn enhancer compositions and methods of using the same | |
SG11201808751SA (en) | T cell receptors | |
SG11201810509PA (en) | Anti-pd-l1 antibodies | |
SG11201909203WA (en) | Tissue selective transgene expression | |
SG11201809710RA (en) | Genetically engineered cells and methods of making the same | |
SG11201906213UA (en) | Modulating expression of polypeptides via new gene switch expression systems | |
SG11201407819UA (en) | Improved methods of cell culture for adoptive cell therapy | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201909331UA (en) | Antigen-specific immune effector cells | |
SG11201907769XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
SG11201911572YA (en) | Adenoviral vectors | |
SG11201805680SA (en) | Methods and compositions for the treatment of neurologic disease | |
SG11201906359SA (en) | Compositions and methods for maturation of oocytes in vitro | |
SG11201810040WA (en) | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors | |
SG11201809473QA (en) | Humanized anti-basigin antibodies and the use thereof | |
SG11201805494WA (en) | Mutated von willebrand factor |